HIKMA

📅 Upcoming

🕒 Recent(90d)

News

• Building a workforce engine for biomanufacturing
  Ohio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.
  fiercebiotech · 29d ago
• Generic drugmakers gain key victory in ‘skinny label’ patent case
  The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
  biopharma_dive · 2mo ago
• STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
  The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.
  stat · 2mo ago
• Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug
  Plus, news about West Pharmaceutical, Stallergenes Greer and Curium: 🏭 Hikma’s US expansion: The generic drugmaker is investing $267 million in Ohio. Its existing factory in Columbus will get $216…
  endpoints · 2mo ago
• Supreme Court sides with Hikma in 'skinny label' case
  The Supreme Court unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was closely watched by the generics industry. T…
  endpoints · 2mo ago
• STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more
  AstraZeneca will resume expansion of its U.K. R&D operations after the trade deal with the U.S. included measures to lift U.K. drug spending
  stat · 3mo ago
• STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
  The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgen
  stat · 3mo ago
• Hikma and Amarin's generic drug case heads to Supreme Court arguments
  When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications o…
  endpoints · 3mo ago
• Pfizer deals extend patent life for a top-selling rare disease drug
  Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
  biopharma_dive · 3mo ago